Decipher Biosciences, a company involved in the field of urologic cancer genomics, has signed a research collaboration with Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, it was reported yesterday.

The collaboration is aimed at implementing genomic tumour profiling using the Decipher assay and GRID software to identify prostate cancer patients on active surveillance who are likely to benefit most from treatment with sipuleucel-T.

Under the contract Dendreon will provide Decipher Biosciences with tumour samples from its Phase three ProVent trial (NCT03686683), which will assess the effectiveness of sipuleucel-T in decreasing disease progression in men with prostate cancer on active surveillance. Decipher Biosciences will utilise its whole transcriptome Decipher assay to evaluate the biological behaviour of a patient's tumour and its GRID software and database to assess gene expression signatures that may be associated with sipuleucel-T response.